Renovaro BioSciences presents insights on Oxford Nanopore sequencing

RenovaroCube announced the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024. This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA derived from blood plasma to detect key copy number alterations in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. “The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations which characterize the copy number landscape of lung cancer tissues-traditionally assessed through tissue biopsy,” said Khashayar Roohollahi, senior scientist at RenovaroCube. Furthermore, CNAs can be used to estimate tumor fractions which is useful for predicting cancer progression and monitoring. The study emphasizes the potential of this technology in reducing the need for invasive tissue biopsies, a significant advancement in oncology.